Latham & Watkins Advises Ascendis Pharma A/S in Public Offering of ADSs

Ascendis Pharma A/S (Nasdaq: ASND) has announced the pricing of its underwritten public offering of 2,000,000 American Depositary Shares (ADSs), each of which represents one ordinary share of Ascendis, at a price to the public of US$150 per ADS. All of the ADSs are being offered by Ascendis. The offering is expected to close on or about September 23, 2024, subject to the satisfaction of customary closing conditions. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 300,000 ADSs at the public offering price, less the underwriting commissions.

Latham & Watkins LLP represents Ascendis Pharma in the offering with a corporate team led by Bay Area partners Mark Roeder and John Williams, with associates Ricky Hanzich, Tyler Israel, Ryleigh Chen, and Yong Jae Kim. Advice was also provided on intellectual property and technology transactions matters by San Diego/Bay Area partner Christopher Hazuka, with associates Kristina Funahashi and Patrick Chew; on tax matters by New York partner Elena Romanova, with associate Allison Esquen-Roca; on compensation and benefits matters by Bay Area partner Maj Vaseghi; on regulatory matters by Washington, D.C. partner Ben Haas, Bay Area partners Betty Pang and Heather Deixler, and Washington, D.C. counsel Chad Jennings; and on EU regulatory matters by Paris/Brussels partner Eveline Van Keymeulen, with associate Jeanne Fabre.